Does chronic immune activation cause low serum iron by upregulating hepcidin?

Chronic immune activation triggers a robust biochemical cascade that fundamentally alters iron metabolism, leading to a state often referred to as the anemia of chronic disease or anemia of inflammation. This process is a coordinated physiological response intended to withhold iron from potential pathogens, though it can lead to functional iron deficiency in the host.

Clinical and effectiveness evidence

In the context of chronic immune activation—seen in conditions ranging from chronic infections to autoimmune disorders and metabolic syndrome—there is a consistent elevation of pro-inflammatory cytokines.

• Cytokine Profile: Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α) are primary markers of this state. For example, in patients with systemic inflammation, IL-6 levels significantly correlate with markers of iron restriction.
• Iron Metrics: Clinical studies show that as IL-6 rises, serum iron and transferrin saturation (TSAT) typically decrease, while serum ferritin (an acute-phase reactant and iron storage protein) increases. This reflects a "functional" rather than "absolute" iron deficiency; the body has iron, but it is locked away.
• Therapeutic Validation: The use of IL-6 inhibitors (such as tocilizumab) in clinical settings has been shown to rapidly decrease hepcidin levels and restore serum iron levels, reinforcing the causal link between these inflammatory signals and iron regulation.

Mechanistic explanations

The transition from immune activation to low serum iron occurs through a highly specific molecular pathway involving the liver and the iron exporter protein, ferroportin.

• Cytokine Signaling: IL-6 is the most potent inducer of hepcidin. It binds to its receptor on hepatocytes, activating the JAK/STAT3 signaling pathway. Phosphorylated STAT3 translocates to the nucleus and binds directly to the promoter of the HAMP gene, which encodes hepcidin.
• Hepcidin Function: Hepcidin acts as the "master regulator" of systemic iron. When levels are high, hepcidin binds to ferroportin, the only known cellular iron exporter found on the surface of macrophages (which recycle iron from old red blood cells) and enterocytes (which absorb dietary iron).
• Sequestration: This binding triggers the internalization and degradation of ferroportin. Without this "exit door," iron remains trapped (sequestered) within these cells. Consequently, the flow of iron into the blood plasma stops, leading to a rapid drop in circulating serum iron.

Bottom line

Chronic immune activation directly increases IL-6 and TNF-α, which stimulate the hepatic production of hepcidin via the JAK/STAT3 pathway. Elevated hepcidin then degrades the iron exporter ferroportin, causing iron to be sequestered within cells and sustaining low serum iron levels.